For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their ...

Employers that cover GLP-1s are partnering with vendors to design benefits and manage lifestyle programs, but the "jury is ...

While grilling Novo Nordisk’s chief executive over the price of its blockbuster diabetes and weight-loss drugs, Ozempic and ...

Novo Nordisk has been criticised by US politicians for the high pricing of its popular weight-loss and diabetes drugs. But ...

Is Ozempic and Wegovy maker Novo Nordisk helping Americans save taxpayer money or ripping them off? The company's CEO ...

Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

GLP-1 weight-loss drugs alleviate obesity as well as provide other health benefits. Yet they are also the focus of ...

What I am asking you is, if you don’t act, 40,000 people a year could die? Is this acceptable to you?” the senator asked.

Sen. Bernie Sanders mentioned that North Carolina ended coverage of Wegovy for state employees due to the cost.

From alcoholism to Parkinson’s, scientists are studying the mechanisms behind the broad clinical potential of weight-loss ...

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...